Video

Dr. Motzer on HRQOL with pembrolizumab plus lenvatinib in advanced RCC

Robert J. Motzer, MD, discusses health-related quality of life (HRQOL) analyses from the phase 3 CLEAR trial of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in patients with metastatic renal cell carcinoma (RCC). According to Motzer, the results showed that the combination resulted in similar HRQOL outcomes and disease-related symptom scores as single-agent sunitinib (Sutent). Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.

Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.